Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

[1]  R. Salgia,et al.  JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies , 2020, JTO clinical and research reports.

[2]  H. Scher,et al.  The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. , 2019, Cancer cell.

[3]  O. Andrén,et al.  M2 macrophages and regulatory T cells in lethal prostate cancer , 2018, The Prostate.

[4]  G. Tortora,et al.  De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. , 2018, Cancer treatment reviews.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  Victor Lira,et al.  Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment , 2018, Proceedings of the National Academy of Sciences.

[7]  S. Barry,et al.  IL-23 secreted by myeloid cells drives castration-resistant prostate cancer , 2018, Nature.

[8]  W. Artibani,et al.  Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review , 2017, Urologia Internationalis.

[9]  K. Gupta,et al.  Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease , 2017, Clinical genitourinary cancer.

[10]  Q. Xie 谢,et al.  Transcriptional regulation of the Nkx3.1 gene in prostate luminal stem cell specification and cancer initiation via its 3′ genomic region , 2017, The Journal of Biological Chemistry.

[11]  E. Antonarakis,et al.  Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer , 2016, Current Urology Reports.

[12]  E. Small,et al.  Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions , 2015, Expert review of vaccines.

[13]  E. Jaffee,et al.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[15]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[16]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[17]  L. Wood,et al.  Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy , 2014, Front. Cell. Infect. Microbiol..

[18]  L. Gomella,et al.  Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy. , 2014, The Canadian journal of urology.

[19]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[20]  A. Wallecha,et al.  Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment , 2013, Journal of Immunotherapy for Cancer.

[21]  S. Khleif,et al.  Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy , 2013, Journal of Immunotherapy for Cancer.

[22]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[23]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[24]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[25]  E. Jaffee,et al.  A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction , 2011, Clinical Cancer Research.

[26]  J. Lang,et al.  Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. , 2011, Cancer research.

[27]  S. Tagawa,et al.  Prostate-Specific Membrane Antigen-Based Therapeutics , 2011, Advances in urology.

[28]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[29]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[30]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. McNeel,et al.  Inducible expression of a prostate cancer‐testis antigen, SSX‐2, following treatment with a DNA methylation inhibitor , 2007, The Prostate.

[32]  M. Giedlin,et al.  Listeria-based cancer vaccines that segregate immunogenicity from toxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  William J Catalona,et al.  Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. , 2004, The Journal of urology.

[34]  R. Cardiff,et al.  Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. , 2002, Cancer research.

[35]  E. Bergstralh,et al.  Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. , 2000, The Journal of urology.

[36]  R. Cardiff,et al.  Roles for Nkx3.1 in prostate development and cancer. , 1999, Genes & development.

[37]  M. Sanda,et al.  Molecular characterization of defective antigen processing in human prostate cancer. , 1995, Journal of the National Cancer Institute.

[38]  F. Saad,et al.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.